Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: Clinical and pathobiological relevance

American Journal of Clinical Pathology

Volumn 140, Issue 4, 2013, Pages 561-566

  Lambein, Kathleen ^a,b   Van Bockstal, Mieke ^a,b   Vandemaele, Lies ^b   Geenen, Sofie ^b   Rottiers, Isabelle ^b   Nuyts, Ann ^b   Matthys, Bart ^b   Praet, Marleen ^a,b   Denys, Hannelore ^b   Libbrecht, Louis ^a,b  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Breast cancer; FISH; HER2; Immunohistochemistry; Score 0; Score 1+

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; COMPARATIVE STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

BREAST CANCER; FISH; HER2; IMMUNOHISTOCHEMISTRY; SCORE 0; SCORE 1+;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MASTECTOMY; QUALITY ASSURANCE, HEALTH CARE; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84884927317     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP4A7KTAYHZSOE     Document Type: Article

References (21)

1. Ross JS, Slodowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320-368.
2. Pinhel I, Hills M, Dryry S, et al. ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res. 2012;14:R46.
3. Gilcrease MZ, Woodward WA, Nicolas MM, et al. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol. 2009;33:759-767.
4. Jensen KC, Nielsen TO, Gilks CB, et al. HER2 intermediate breast cancers. Am J Surg Pathol. 2009;33:1739-1740.
5. Gilcrease MZ. In response to Jensen KC, et al. Am J Surg Pathol. 2009;33:1739-1740.
6. Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
7. Walker RA, Bartlett JMS, Dowsett M, et al. HER2 testing in the UK: further update to recommendations. J Clin Pathol. 2008;61:818-824. (Pubitemid 351969725)
8. Barrett C, Magee H, O'Toole D, et al. Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or falsenegative immunohistochemistry? J Clin Pathol. 2007;60:690-693. (Pubitemid 46975227)
9. Lal P, Salazar PA, Hudis CA, et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization. Am J Clin Pathol. 2004;121:631-636.
10. Gunn S, Yeh IT, Lytvak I, et al. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity. BMC Cancer. 2010;10:396.
11. Egervari K, Kosa C, Szollosi Z. Impact of chromosome 17 centromere region assessment on HER2 status reported in breast cancer. Pathol Res Pract. 2011;207:468-471.
12. Hammond ME, Hayes DF, Wolff AC. Clinical notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol. 2001;29:e458.
13. Clay MR, Iberri DJ, Bangs CD, et al. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution. Am J Surg Pathol. 2013;37:120-127.
14. Colpaert C, Salgado R. Belgian guidelines for HER2/neu testing in breast cancer. BJMO. 2007;1:22-29.
15. Schrohl AS, Pedersen HC, Jenssen SS, et al. Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies. Histopathology. 2011;59:975-983.
16. Jay JI, Brunhoeber PS, Smith MH, et al. Immunohistochemical analysis of the monoclonal antibody 4B5 in breast tissue expressing human epidermal growth factor receptor 4 (HER4). Histopathology. 2013;62:563-577.
17. Dekker TJ, Borg ST, Hooijer GK, et al. Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Res. 2012;14:R93.
18. D'Alfonso T, Liu YF, Monni S, et al. Accurately assessing Her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed. Am J Surg Pathol. 2010;34:575-581.
19. Vergara-Lluri ME, Moatamed MA, Hong E, et al. High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/ College of American Pathology 2007 guidelines. Mod Pathol. 2012;25:1326-1332.
20. Grimm EE, Schmidt RA, Swanson PE, et al. Achieving 95% cross-methodological concordance in HER2 testing. Am J Clin Pathol. 2010;134:284-292.
21. Zarbo RJ, Hammond ME. Conference summary, Strategic Science symposium: Her-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med. 2003;127:549-553. (Pubitemid 36534937)